tolerogenic dendritic cells (tolDC)

BIOLOGICAL3 trials

Sponsors

University Hospital, Antwerp

Conditions

Multiple Sclerosis

Phase 1

A negativedendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial

CompletedNCT02618902

University Hospital, AntwerpMultiple Sclerosis

Start: 2017-05-30End: 2022-02-03Updated: 2024-12-09

Phase 2

A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS

WithdrawnNCT06715605

University Hospital, AntwerpMultiple Sclerosis

Start: 2025-04-30End: 2027-10-29Updated: 2025-08-17

A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis

Not yet recruitingNCT07020715

University Hospital, AntwerpMultiple Sclerosis

Start: 2026-07-01End: 2029-10-30Target: 14Updated: 2026-05-05

Related Papers

Design of TOLERANT: phase I/II safety assessment of intranodal administration of HSP70/mB29a self-peptide antigen-loaded autologous tolerogenic dendritic cells in patients with rheumatoid arthritis

BMJ Open2024-09-018 citations

Abstracts from the 37th Annual Meeting of the Consortium of Multiple Sclerosis Centers: May 31-June 3, 2023 · Aurora, Colorado

International Journal of MS Care2023-05-01

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration

BMJ Open2019-09-0197 citations